



- (51) **International Patent Classification:**
C07D 209/20 (2006.01) *A61K 31/404* (2006.01)
- (21) **International Application Number:**
PCT/US2024/035610
- (22) **International Filing Date:**
26 June 2024 (26.06.2024)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/523,377 27 June 2023 (27.06.2023) US
63/523,378 27 June 2023 (27.06.2023) US
- (71) **Applicants:** SHIH, Chuan [US/CN]; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd. Nangang Dist., Taipei City 11571 (TW). ANBOGEN THERAPEUTICS INC. [CN/CN]; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd. Nangang Dist., Taipei City 11571 (TW).
- (72) **Inventors:** HSU, Tsu-An; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd. Nangang Dist., Taipei City 11571 (TW). CHANG, Sue-Ming; Room C523, Building C, No. 99, Ln. 130, Sec. 1, Academia Rd. Nangang Dist., Taipei City 11571 (TW).
- (74) **Agent:** CANFIELD, Floyd; Muncy, Geissler, Olds & Lowe, P.C., 125 S. Royal St., Alexandria, Virginia 22314 (US).
- (81) **Designated States** (*unless otherwise indicated, for every kind of national protection available*): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(54) **Title:** CRYSTALLINE FORMS OF (E)-N-HYDROXY-3-(1-(PHENYLSULFONYL)INDOLIN-5-YL)ACRYLAMIDE




FIG. 35

(57) **Abstract:** Disclosed herein is a specific crystalline forms of (E)-N-hydroxy-3-(1-(phenylsulfonyl)indolin-5-yl)acrylamide (ABT-301), the pharmaceutical composition and capsule comprising the same, the intermediate and the medical application thereof. Said crystalline forms of ABT-301 can exhibit unexpected stability and improved pharmacokinetic properties compared to other forms or salt thereof, thereby allowing said compound more suitable for drug development and satisfying the requirements for bioavailability and drug efficacy.

[Continued on next page]

(84) Designated States (*unless otherwise indicated, for every kind of regional protection available*): ARIPO (BW, CV, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— with international search report (Art. 21(3))